These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2093542)

  • 1. rhEPO treatment of anemia in uremic patients.
    Bommer J; Barth HP; Schwöbel B
    Contrib Nephrol; 1990; 87():59-67. PubMed ID: 2093542
    [No Abstract]   [Full Text] [Related]  

  • 2. Correction of anaemia with recombinant human erythropoietin.
    Ponticelli C; Casati S
    Nephron; 1989; 52(3):201-8. PubMed ID: 2662045
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug delivery optimization through Bayesian networks.
    Bellazzi R
    Proc Annu Symp Comput Appl Med Care; 1992; ():572-8. PubMed ID: 1482938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacodynamic model of erythropoietin therapy for uremic anemia.
    Uehlinger DE; Gotch FA; Sheiner LB
    Clin Pharmacol Ther; 1992 Jan; 51(1):76-89. PubMed ID: 1732079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin and peritoneal dialysis: the efficacy of intraperitoneal dosing.
    Nissenson AR
    Perit Dial Int; 1992; 12(4):350-2. PubMed ID: 1420491
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
    Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminium interference in the treatment with recombinant human erythropoietin.
    Casati S; Campise M; Ponticelli C
    Contrib Nephrol; 1990; 87():87-94. PubMed ID: 2093544
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recombinant human erythropoietin in uremic patients in substitute treatment].
    Canaud B; Mion C
    Rev Prat; 1992 Feb; 42(4):432-40. PubMed ID: 1604162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure.
    Savica V; Costantino G; Monardo P; Bellinghieri G
    Am J Nephrol; 1995; 15(1):10-4. PubMed ID: 7872358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 12. L-Carnitine effects on anemia in uremic rats treated with erythropoietin.
    Azzadin A; Wollny T; Pawlak R; Malyszko JS; Malyszko J; Myśliwiec M; Buczko W
    Nephron; 1999; 83(4):370-1. PubMed ID: 10575305
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease.
    Koene RA; Frenken LA
    Kidney Int Suppl; 1992 Oct; 38():S142-7. PubMed ID: 1405365
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term persistence of improvement of renal anaemia in spite of discontinued erythropoietin treatment.
    Wiecek A; Kokot F; Marcinkowski W
    Nephron; 1995; 69(4):489-90. PubMed ID: 7777122
    [No Abstract]   [Full Text] [Related]  

  • 16. Does anemia correction by rHuEPO improve uremic cardiopathy?
    Carletti P; Bibiano L; Boggi R; Taruscia D; Mioli V
    Kidney Int Suppl; 1993 Jun; 41():S70-1. PubMed ID: 8320949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin therapy. Part I: clinical issues.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):1-34. PubMed ID: 2928605
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoietin for anemia.
    Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
    [No Abstract]   [Full Text] [Related]  

  • 19. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
    Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
    Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.